JFG
CORT icon

Jefferies Financial Group’s Corcept Therapeutics CORT Stock Holding History

Jefferies Financial Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,081
Closed -$2.02M – 1817
2025
Q4 		$2.02M Buy
+58,081
New +$4.56M 0.01% 805
2024
Q2 		– Sell
-103,553
Closed -$2.61M – 1480
2024
Q1 		$2.61M Buy
+103,553
New +$2.45M 0.02% 504

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Jefferies Financial Group's CORT Position: Q1 2026 in Review

Jefferies Financial Group sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 58,081 shares — an estimated $2.02M sold.

Jefferies Financial Group first reported a position in CORT in Q1 2024 and held it in 2 quarters. The position peaked at $2.61M in Q1 2024. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Jefferies Financial Group reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 58,081 Corcept Therapeutics shares in Q1 2026, an estimated $2.02M.
  • Jefferies Financial Group first reported a position in Corcept Therapeutics in Q1 2024 and held it in 2 quarters.
  • Jefferies Financial Group's Corcept Therapeutics position peaked at $2.61M in Q1 2024.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.